RG
CNTA

Rathbones Group’s Centessa Pharmaceuticals CNTA Stock Holding History

Rathbones Group’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,500
Closed -$217K – 645
2025
Q2 		$217K Hold
16,500
– – ﹤0.01% 544
2025
Q1 		$237K Sell
16,500
-150
-0.9% -$2.45K ﹤0.01% 501
2024
Q4 		$279K Sell
16,650
-13,750
-45% -$228K ﹤0.01% 479
2024
Q3 		$486K Sell
30,400
-900
-3% -$11K ﹤0.01% 420
2024
Q2 		$283K Hold
31,300
– – ﹤0.01% 498
2024
Q1 		$354K Hold
31,300
– – ﹤0.01% 461
2023
Q4 		$249K Hold
31,300
– – ﹤0.01% 501
2023
Q3 		$203K Buy
+31,300
New +$214K ﹤0.01% 538

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return